ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Bladder Cancer

MBCC 2016 hero

Bladder Cancer

In this interview we discuss predictive biomarkers and response to immune checkpoint inhibitors for urothelial tumors, which include tumors of the bladder, ureters, and the renal pelvis.

An observational study found that adjuvant chemotherapy improves overall survival in patients with locally advanced bladder cancer.

An Egyptian study found that bladder cancer patients who underwent radical cystectomy had better local recurrence-free survival with adjuvant radiotherapy and chemotherapy combined, compared with chemotherapy alone.

The anti-PD-L1 antibody atezolizumab showed significantly improved objective response rates compared to historic controls in a phase II study of patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy.

Comprehensive genomic profiling of patients with advanced urothelial carcinoma has revealed a very high frequency of clinically relevant genomic alterations.

Patients with metastatic or unresectable urothelial carcinoma who are treated with either carboplatin or cisplatin have high rates of vascular thromboembolic events.

A phase II trial found that use of a personalized peptide vaccination improved overall survival in patients with chemotherapy-resistant advanced urothelial bladder cancer.

Pages

Subscribe to Bladder Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.